


an iminophosphorane with the carbonyl substituents of the resin. Thus, Applicants submit that Groups II, III, and IV should be combined into one group. At a minimum, claims 44, 45, 47, and 49-53 should be consolidated into a single group. Accordingly, Applicants respectfully request that the Examiner reconsider the restriction requirement between Groups II, III, and IV.

Respectfully submitted,



Stephen L. Nesbitt, Attorney
Registration No. 28,981

Date: 2/1/02

Pharmacia & Upjohn Company
Global Intellectual Property
301 Henrietta Street
Kalamazoo, Michigan 49001

Telephone No. (616) 833-1837 or (616) 833-9500
Telefax No. (616) 833-8897 or (616) 833-2316